Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$3.1MCash on Hand
9.4mo Cash Runway
Follow KAPA by emailGet an email when KAPA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about KAPA, unsubscribe in one click. Privacy
📣 What KAPA Says Is Next
fourth quarter of 2027 · “The protocol modification is intended to expand the eligible patient population and facilitate enrollment, with Kairos Pharma targeting completion of the Phase 2 trial in or before the fourth quarter of 2027.”
Company press release, Oct 6, 2026 · SEC filing
in 2026 · “CL-741 is a Phase 1-ready therapeutic candidate targeting EGFR-mutated lung cancer, a treatment landscape valued at an estimated $16.2B in 2026 ( Future Market Insights ).”
Company press release, Jun 4, 2026 · SEC filing
in 2026 · “The program is currently pre-IND, with first-in-human clinical trials projected to commence in 2026.”
Company press release, Feb 26, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 5, 2026 ·
Kairos Pharma said its ENV-105 (carotuximab) program was named a winner of the 2026 Biotech Breakthrough Awards in the Cancer Immunology Solution of the Year category. Form 8-K · SEC filing · Press release
Nov 3, 2026 ·
Financing Kairos amended its equity line of credit with Helena Global three times: the purchase price was set at 97% of average daily VWAP, the pricing period was cut to one Trading Day, and the facility was extended to December 31, 2028. Dr. Bhowmick presented interim ENV-105 efficacy data at a Houston conference. Form 8-K · SEC filing · Press release
Oct 6, 2026 ·
Clinical trial Reported interim Phase 2 data for ENV-105 (carotuximab) plus apalutamide in metastatic castration-resistant prostate cancer, with median progression-free survival of 17.7 months versus 2 months for apalutamide alone (P=0.0008). Form 8-K · SEC filing · Press release
Sep 14, 2026 ·
Kairos Pharma issued a new investor presentation on Sep 14, 2026, to be posted on its website and presented by CEO John Yu at the H.C. Wainwright 28th Annual Global Investment Conference in New York, Sep 14-16, 2026. The filing gives no new clinical data. Form 8-K · SEC filing · Press release
Aug 21, 2026 ·
Listing Kairos Pharma approved a 1-for-7 reverse stock split of its common stock, effective September 1, 2026, with trading under the symbol KAPA on NYSE American and a new CUSIP of 48301N203. Fractional shares will be rounded up to a whole share. Form 8-K · SEC filing · Press release
Aug 12, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
Also used in these trials (approved or third-party drugs, not KAPA's own candidates): Apalutamide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
KAPA holds $3.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $995,500/quarter from operations,
an estimated runway of 9.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:70 · High
Cash runway 8 months +30
ATM program on file since Jan 2026 +15
Shelf registration (S-3, Jan 2026) +10
Going-concern doubt in the latest 10-Q +15These factors raise substantial doubt about the Company’s ability to continue as a going concern.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Jan 13, 2026 · Shelf registration with ATM program, up to $5M · S-3
Share count 4,685,025 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full KAPA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KAPA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.